Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04880434
Title Study to Evaluate the Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 3) (ZUMA-2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Kite, A Gilead Company
Indications

mantle cell lymphoma

Therapies

Brexucabtagene autoleucel + Cyclophosphamide + Fludarabine

Age Groups: adult | senior
Covered Countries USA | FRA | ESP | DEU


No variant requirements are available.